Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

Biochemical and Biophysical Research Communications

Volumn 333, Issue 2, 2005, Pages 328-335

  Ferrara, Napoleone ^a   Hillan, Kenneth J ^a   Novotny, William ^a  

^a GENENTECH INC   (United States)

Author keywords

Angiogenesis; Chemotherapy; Endothelium; Monoclonal antibodies; Tumor; VEGF

Indexed keywords

AG 013676; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG SAFETY; ENDOTHELIUM; EPISTAXIS; FOOD AND DRUG ADMINISTRATION; GENE CONTROL; GENE EXPRESSION; HUMAN; HYPERTENSION; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; TUMOR CELL LINE; TUMOR GROWTH; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS MUSCULUS;

EID: 20544455330     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.05.132     Document Type: Review

References (96)

1. N. Ferrara VEGF and the quest for tumour angiogenesis factors Nat. Rev. Cancer 2 2002 795 803
2. A.G. Ide, N.H. Baker, and S.L. Warren Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber Am. J. Roentgenol. 42 1939 891 899
3. M. Greenblatt, and P. Shubick Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparentchamber technique J. Natl. Cancer Inst. 41 1968 111 124
4. R.L. Ehrmann, and M. Knoth Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy J. Natl. Cancer Inst. 41 1968 1329 1341
5. J. Folkman Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 285 1971 1182 1186
6. M. Klagsbrun, and P.A. D'Amore Regulators of angiogenesis Annu. Rev. Physiol. 53 1991 217 239
7. G.D. Yancopoulos, S. Davis, N.W. Gale, J.S. Rudge, S.J. Wiegand, and J. Holash Vascular-specific growth factors and blood vessel formation Nature 407 2000 242 248
8. N. Ferrara, K.J. Hillan, H.P. Gerber, and W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat. Rev. Drug Discov. 3 2004 391 400
9. D.R. Senger, S.J. Galli, A.M. Dvorak, C.A. Perruzzi, V.S. Harvey, and H.F. Dvorak Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 219 1983 983 985
10. N. Ferrara, and W.J. Henzel Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells Biochem. Biophys. Res. Commun. 1989 851 858
11. D.T. Connolly, J.V. Olander, D. Heuvelman, R. Nelson, R. Monsell, N. Siegel, B.L. Haymore, R. Leimgruber, and J. Feder Human vascular permeability factor. Isolation from U937 cells J. Biol. Chem. 264 1989 20017 20024
12. D.W. Leung, G. Cachianes, W.J. Kuang, D.V. Goeddel, and N. Ferrara Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 1989 1306 1309
13. P.J. Keck, S.D. Hauser, G. Krivi, K. Sanzo, T. Warren, J. Feder, and D.T. Connolly Vascular permeability factor, an endothelial cell mitogen related to PDGF Science 246 1989 1309 1312
14. K.A. Houck, N. Ferrara, J. Winer, G. Cachianes, B. Li, and D.W. Leung The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA Mol. Endocrinol. 5 1991 1806 1814
15. E. Tischer, R. Mitchell, T. Hartman, M. Silva, D. Gospodarowicz, J.C. Fiddes, and J.A. Abraham The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing J. Biol. Chem. 266 1991 11947 11954
16. N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr. Rev. 25 2004 581 611
17. K.A. Houck, D.W. Leung, A.M. Rowland, J. Winer, and N. Ferrara Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms J. Biol. Chem 267 1992 26031 26037
18. J.E. Park, G.-A. Keller, and N. Ferrara The vascular endothelial growth factor isoforms (VEGF): differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF Mol. Biol. Cell 4 1993 1317 1326
19. B.A. Keyt, L.T. Berleau, H.V. Nguyen, H. Chen, H. Heinsohn, R. Vandlen, and N. Ferrara The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency J. Biol. Chem. 271 1996 7788 7795
20. N. Ferrara, K. Carver Moore, H. Chen, M. Dowd, L. Lu, K.S. O'Shea, L. Powell Braxton, K.J. Hillan, and M.W. Moore Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene Nature 380 1996 439 442
21. H.P. Gerber, A. McMurtrey, J. Kowalski, M. Yan, B.A. Keyt, V. Dixit, and N. Ferrara VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction Pathway. requirement for Flk-1/KDR activation J. Biol. Chem. 273 1998 30343 30366
22. H.P. Gerber, V. Dixit, and N. Ferrara Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells J. Biol. Chem. 273 1998 13313 13316
23. F. Yuan, Y. Chen, M. Dellian, N. Safabakhsh, N. Ferrara, and R.K. Jain Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody Proc. Natl. Acad. Sci. USA 93 1996 14765 14770
24. L.E. Benjamin, D. Golijanin, A. Itin, D. Pode, and E. Keshet Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal J. Clin. Invest. 103 1999 159 165
25. H.F. Dvorak Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J. Clin. Oncol. 20 2002 4368 4380
26. P. Carmeliet Blood vessels and nerves: common signals, pathways and diseases Nat. Rev. Genet. 4 2003 710 720
27. M. Shibuya, S. Yamaguchi, A. Yamane, T. Ikeda, A. Tojo, H. Matsushime, and M. Sato Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family Oncogene 8 1990 519 527
28. C. de Vries, J.A. Escobedo, H. Ueno, K. Houck, N. Ferrara, and L.T. Williams The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor Science 255 1992 989 991
29. B.I. Terman, M. Dougher Vermazen, M.E. Carrion, D. Dimitrov, D.C. Armellino, D. Gospodarowicz, and P. Bohlen Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor Biochem. Biophys. Res. Commun. 187 1992 1579 1586
30. B. Millauer, S. Wizigmann Voos, H. Schnurch, R. Martinez, N.P. Moller, W. Risau, and A. Ullrich High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis Cell 72 1993 835 846 Issue No: 0092-8674.
31. T.P. Quinn, K.G. Peters, C. De Vries, N. Ferrara, and L.T. Williams Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium Proc. Natl. Acad. Sci. USA 90 1993 7533 7537
32. J.E. Park, H.H. Chen, J. Winer, K.A. Houck, and N. Ferrara Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR J. Biol. Chem. 269 1994 25646 25654
33. K. Hattori, B. Heissig, Y. Wu, S. Dias, R. Tejada, B. Ferris, D.J. Hicklin, Z. Zhu, P. Bohlen, L. Witte, J. Hendrikx, N.R. Hackett, R.G. Crystal, M.A. Moore, Z. Werb, D. Lyden, and S. Rafii Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment Nat. Med. 8 2002 841 849
34. H.-P. Gerber, A. Malik, G.P. Solar, D. Sherman, X.-H. Liang, G. Meng, K. Hong, J. Marsters, and N. Ferrara Vascular endothelial growth factor regulates hematopoietic stem cell survival by an internal autocrine loop mechanism Nature 417 2002 954 958
35. B. Barleon, S. Sozzani, D. Zhou, H.A. Weich, A. Mantovani, and D. Marme Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1 Blood 87 1996 3336 3343
36. A. Luttun, M. Tjwa, L. Moons, Y. Wu, A. Angelillo-Scherrer, F. Liao, J.A. Nagy, A. Hooper, J. Priller, B. De Klerck, V. Compernolle, E. Daci, P. Bohlen, M. Dewerchin, J.M. Herbert, R. Fava, P. Matthys, G. Carmeliet, D. Collen, H.F. Dvorak, D.J. Hicklin, and P. Carmeliet Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 Nat. Med. 8 2002 831 840
37. S. Hiratsuka, K. Nakamura, S. Iwai, M. Murakami, T. Itoh, H. Kijima, J.M. Shipley, R.M. Senior, and M. Shibuya MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis Cancer Cell 2 2002 289 300
38. J. LeCouter, D.R. Moritz, B. Li, G.L. Phillips, X.H. Liang, H.P. Gerber, K.J. Hillan, and N. Ferrara Angiogenesis-independent endothelial protection of liver: role of VEGFR-1 Science 299 2003 890 893
39. S. Soker, S. Takashima, H.Q. Miao, G. Neufeld, and M. Klagsbrun Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor Cell 92 1998 735 745
40. M. Safran, and W.J. Kaelin Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway J. Clin. Invest. 111 2003 779 783
41. D.R. Mole, P.H. Maxwell, C.W. Pugh, and P.J. Ratcliffe Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing IUBMB Life 52 2001 43 47
42. R.R. Lonser, G.M. Glenn, M. Walther, E.Y. Chew, S.K. Libutti, W.M. Linehan, and E.H. Oldfield von Hippel-Lindau disease Lancet 361 2003 2059 2067
43. P.H. Maxwell, M.S. Wiesener, G.W. Chang, S.C. Clifford, E.C. Vaux, M.E. Cockman, C.C. Wykoff, C.W. Pugh, E.R. Maher, and P.J. Ratcliffe The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 399 1999 271 275
44. 2-regulated prolyl hydroxylation Science 292 2001 468 472
45. 2 sensing Science 292 2001 464 468
46. S. Grugel, G. Finkenzeller, K. Weindel, B. Barleon, and D. Marme Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells J. Biol. Chem. 270 1995 25915 25919
47. F. Okada, J.W. Rak, B.S. Croix, B. Lieubeau, M. Kaya, L. Roncari, S. Shirasawa, T. Sasazuki, and R.S. Kerbel Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells Proc. Natl. Acad. Sci. USA 95 1998 3609 3614
48. Y.-P. Shi, and N. Ferrara Oncogenic ras fails to restore an in vivo oncogenic phenotype in embryonic stem cells lacking VEGF Biochem. Biophys. Res. Commun. 254 1999 480 483
49. X. Zhang, J.P. Gaspard, and D.C. Chung Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia Cancer Res. 61 2001 6050 6054
50. M. Volm, R. Koomagi, and J. Mattern Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer Int. J. Cancer 74 1997 64 68
51. H. Yoshiji, D.E. Gomez, M. Shibuya, and U.P. Thorgeirsson Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer Cancer Res. 56 1996 2013 2016
52. L.M. Ellis, Y. Takahashi, C.J. Fenoglio, K.R. Cleary, C.D. Bucana, and D.B. Evans Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma Eur. J. Cancer 34 1998 337 340
53. M. Tomisawa, T. Tokunaga, Y. Oshika, T. Tsuchida, Y. Fukushima, H. Sato, H. Kijima, H. Yamazaki, Y. Ueyama, N. Tamaoki, and M. Nakamura Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma Eur. J. Cancer 35 1999 133 137
54. H.M. Sowter, A.N. Corps, A.L. Evans, D.E. Clark, D.S. Charnock-Jones, and S.K. Smith Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors Lab. Invest 77 1997 607 614
55. J. Brugarolas, and W.G. Kaelin Jr. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes Cancer Cell 6 2004 7 10
56. K.J. Kim, B. Li, J. Winer, M. Armanini, N. Gillett, H.S. Phillips, and N. Ferrara Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo Nature 362 1993 841 844
57. R.S. Warren, H. Yuan, M.R. Matli, N.A. Gillett, and N. Ferrara Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis J. Clin. Invest. 95 1995 1789 1797
58. O. Melnyk, M.A. Shuman, and K.J. Kim Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth Cancer Res. 56 1996 921 924
59. P. Borgstrom, K.J. Hillan, P. Sriramarao, and N. Ferrara Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy Cancer Res. 56 1996 4032 4039
60. P. Borgstrom, M.A. Bourdon, K.J. Hillan, P. Sriramarao, and N. Ferrara Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo Prostate 35 1998 1 10
61. M. Asano, A. Yukita, T. Matsumoto, S. Kondo, and H. Suzuki Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121 Cancer Res. 55 1995 5296 5301
62. B. Millauer, L.K. Shawver, K.H. Plate, W. Risau, and A. Ullrich Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant Nature 367 1994 576 579
63. L.M. Strawn, G. McMahon, H. App, R. Schreck, W.R. Kuchler, M.P. Longhi, T.H. Hui, C. Tang, A. Levitzki, A. Gazit, I. Chen, G. Keri, L. Orfi, W. Risau, I. Flamme, A. Ullrich, K.P. Hirth, and L.K. Shawver Flk-1 as a target for tumor growth inhibition Cancer Res. 56 1996 3540 3545
64. J.M. Wood, G. Bold, E. Buchdunger, R. Cozens, S. Ferrari, J. Frei, F. Hofmann, J. Mestan, H. Mett, T. O'Reilly, E. Persohn, J. Rosel, C. Schnell, D. Stover, A. Theuer, H. Towbin, F. Wenger, K. Woods-Cook, A. Menrad, G. Siemeister, M. Schirner, K.H. Thierauch, M.R. Schneider, J. Drevs, G. Martiny-Baron, and F. Totzke PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Res. 60 2000 2178 2189
65. S.R. Wedge, D.J. Ogilvie, M. Dukes, J. Kendrew, J.O. Curwen, L.F. Hennequin, A.P. Thomas, E.S. Stokes, B. Curry, G.H. Richmond, and P.F. Wadsworth ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy Cancer Res. 60 2000 970 975
66. T. Oku, J.G. Tjuvajev, T. Miyagawa, T. Sasajima, A. Joshi, R. Joshi, R. Finn, K.P. Claffey, and R.G. Blasberg Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts Cancer Res. 58 1998 4185 4192
67. M. Prewett, J. Huber, Y. Li, A. Santiago, W. O'Connor, K. King, J. Overholser, A. Hooper, B. Pytowski, L. Witte, P. Bohlen, and D.J. Hicklin Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis Cancer Res. 59 1999 5209 5218
68. H.P. Gerber, J. Kowalski, D. Sherman, D.A. Eberhard, and N. Ferrara Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor Cancer Res. 60 2000 6253 6258
69. J. Holash, S. Davis, N. Papadopoulos, S.D. Croll, L. Ho, M. Russell, P. Boland, R. Leidich, D. Hylton, E. Burova, E. Ioffe, T. Huang, C. Radziejewski, K. Bailey, J.P. Fandl, T. Daly, S.J. Wiegand, G.D. Yancopoulos, and J.S. Rudge VEGF-trap: a VEGF blocker with potent antitumor effects Proc. Natl. Acad. Sci. USA 99 2002 11393 11398
70. D. Fukumura, R. Xavier, T. Sugiura, Y. Chen, E.C. Park, N. Lu, M. Selig, G. Nielsen, T. Taksir, R.K. Jain, and B. Seed Tumor induction of VEGF promoter activity in stromal cells Cell 94 1998 715 725
71. J. Dong, J. Grunstein, M. Tejada, F. Peale, G. Frantz, W.C. Liang, W. Bai, L. Yu, J. Kowalski, X. Liang, G. Fuh, H.P. Gerber, and N. Ferrara VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis EMBO J. 23 2004 2800 2810
72. G. Klement, S. Baruchel, J. Rak, S. Man, K. Clark, D.J. Hicklin, P. Bohlen, and R.S. Kerbel Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J. Clin. Invest. 105 2000 R15 R24
73. C.G. Lee, M. Heijn, E. di Tomaso, G. Griffon-Etienne, M. Ancukiewicz, C. Koike, K.R. Park, N. Ferrara, R.K. Jain, H.D. Suit, and Y. Boucher Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions Cancer Res. 60 2000 5565 5570
74. S.V. Kozin, Y. Boucher, D.J. Hicklin, P. Bohlen, R.K. Jain, and H.D. Suit Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts Cancer Res. 61 2001 39 44
75. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat. Med. 7 2001 987 989
76. C.D. Pham, T.P. Roberts, N. van Bruggen, O. Melnyk, J. Mann, N. Ferrara, R.L. Cohen, and R.C. Brasch Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor Cancer Invest. 16 1998 225 230
77. C.G. Willett, Y. Boucher, E. Di Tomaso, D.G. Duda, L.L. Munn, R.T. Tong, D.C. Chung, D.V. Sahani, S.P. Kalva, S.V. Kozin, M. Mino, K.S. Cohen, D.T. Scadden, A.C. Hartford, A.J. Fischman, J.W. Clark, D.P. Ryan, A.X. Zhu, L.S. Blaszkowsky, H.X. Chen, P.C. Shellito, G.Y. Lauwers, and R.K. Jain Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat. Med. 10 2004 145 147
78. L.G. Presta, H. Chen, S.J. O'Connor, V. Chisholm, Y.G. Meng, L. Krummen, M. Winkler, and N. Ferrara Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res. 57 1997 4593 4599
79. Y.A. Muller, Y. Chen, H.W. Christinger, B. Li, B.C. Cunningham, H.B. Lowman, and A.M. de Vos VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface Structure 6 1998 1153 1167
80. Y.S. Lin, C. Nguyen, J.L. Mendoza, E. Escandon, D. Fei, Y.G. Meng, and N.B. Modi Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor J. Pharmacol. Exp. Ther. 288 1999 371 378
81. H.P. Gerber, and N. Ferrara Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res. 65 2005 671 680
82. A.M. Ryan, D.B. Eppler, K.E. Hagler, R.H. Bruner, P.J. Thomford, R.L. Hall, G.M. Shopp, and C.A. O'Neill Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody Toxicol. Pathol. 27 1999 78 86
83. D.T. Shima, A. Gougos, J.W. Miller, M. Tolentino, G. Robinson, A.P. Adamis, and P.A. D'Amore Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis Invest. Ophthalmol. Vis. Sci. 37 1996 1334 1340
84. H.P. Gerber, T.H. Vu, A.M. Ryan, J. Kowalski, Z. Werb, and N. Ferrara VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation Nat. Med. 5 1999 623 628
85. K. Margolin, M.S. Gordon, E. Holmgren, J. Gaudreault, W. Novotny, G. Fyfe, D. Adelman, S. Stalter, and J. Breed Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data J. Clin. Oncol. 19 2001 851 856
86. M.S. Gordon, K. Margolin, M. Talpaz, G.W. Sledge Jr., E. Holmgren, R. Benjamin, S. Stalter, S. Shak, and D. Adelman Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J. Clin. Oncol. 19 2001 843 850
87. F. Kabbinavar, H.I. Hurwitz, L. Fehrenbacher, N.J. Meropol, W.F. Novotny, G. Lieberman, S. Griffing, and E. Bergsland Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J. Clin. Oncol. 21 2003 60 65
88. R. DeVore, R.S. Herbst, C.J. Langer, K. Kelly, J. Gaudreault, E. Holmgren, W.F. Novotny, F. Kabbinavar, A randomized Phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus Carboplatin/Paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC, 36th ASCO Annual Meeting, New Orleans, Louisiana, 2000. (2000).
89. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, S.L. Tapalian, S.M. Steinberg, H.X. Chen, and S.A. Rosenberg A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer N. Engl. J. Med. 349 2003 427 434
90. L.B. Saltz, J.Y. Douillard, N. Pirotta, M. Alakl, G. Gruia, L. Awad, G.L. Elfring, P.K. Locker, and L.L. Miller Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard Oncologist 6 2001 81 91
91. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, H. Hainsworth, W. Helm, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, and F. Kabbinavar Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 2004 2335 2342
92. R.M. Goldberg, D.J. Sargent, R.F. Morton, C.S. Fuchs, R.K. Ramanathan, S.K. Williamson, B.P. Findlay, H.C. Pitot, and S.R. Alberts A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J. Clin. Oncol. 22 2004 23 30
93. K.D. Miller, H.S. Rugo, M.A. Cobleigh, P.K. Marcom, L.I. Chap, and F.A. Holmes Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastine) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane Breast Cancer Res. Treat. 76 2002 S37
94. J.K. Smith, N.M. Mamoon, and R.J. Duhe Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy Oncol. Res. 14 2004 175 225
95. B. Morgan, A.L. Thomas, J. Drevs, J. Hennig, M. Buchert, A. Jivan, M.A. Horsfield, K. Mross, H.A. Ball, L. Lee, W. Mietlowski, S. Fuxuis, C. Unger, K. O'Byrne, A. Henry, G.R. Cherryman, D. Laurent, M. Dugan, D. Marme, and W.P. Steward Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies J. Clin. Oncol. 21 2003 3955 3964
96. H.P. Gerber, and N. Ferrara The role of VEGF in normal and neoplastic hematopoiesis J. Mol. Med. 81 2003 20 31